The biologics market reached a valuation of USD 419.07 billion in 2023, and it is projected to soar to USD 845.78 billion by 2033. With an anticipated Compound Annual Growth Rate (CAGR) of 7.6% by 2032, the market is set for significant expansion, driven by ongoing advancements in biotechnology, increasing healthcare needs, and the rising demand for innovative treatments across various therapeutic areas.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5108
The biologics market reached an impressive USD 419.07 billion in 2023, with projections suggesting it will grow to USD 845.78 billion by 2033. This growth is expected to come with a 7.6% annual growth rate by 2032. Blood and blood products dominated the market in 2023, holding a significant 66% share. Oncology emerged as the leading application, accounting for 36% of the market. Looking ahead, the Asia Pacific region is expected to experience the fastest growth over the next decade.
Artificial intelligence (AI) is set to revolutionize the biologics market by enhancing drug development and manufacturing processes. AI can accelerate the discovery of biologics, such as monoclonal antibodies and vaccines, by analyzing large datasets to identify promising candidates and predict their effectiveness. Machine learning algorithms are helping to streamline drug discovery, reducing both time and costs while increasing accuracy.
In clinical trials, AI plays a key role in improving patient recruitment by analyzing electronic health records and genetic data to identify the best candidates. This leads to more efficient trials with higher success rates. AI also helps optimize trial design, predict patient responses, and reduce risks, making data analysis more accurate.
During biologics production, AI-powered automation and predictive analytics improve process control, leading to better yields and consistent product quality. Real-time monitoring of production processes allows AI systems to detect anomalies and adjust parameters as needed. Furthermore, AI enables personalized medicine by analyzing patient data to tailor biologic therapies to individual needs, creating new opportunities in the market.
In July 2024, Flagship Pioneering introduced biologic medications using novel building blocks not found in nature. These proteins are claimed to have superior qualities compared to other medications, focusing on innovative therapies for immunology and cancer.
In May 2024, Commit Biologics launched from stealth mode with €16 million ($17.2 million) in seed funding. The company is developing antibody therapies for cancer and autoimmune diseases using their bispecific complement engaging (BiCE) technology, backed by investors like Novo Nordisk’s Novo Holdings and Bioqube Ventures.
Bone Biologics, specializing in spine fusion implants, announced an IPO in March 2024, raising $2 million. The company plans to use the funds for clinical research, working capital, and expanding its patent portfolio.
In January 2024, Sandoz and Coherus BioSciences acquired the biosimilar ranibizumab Cimerli for $170 million, including product inventory, sales staff, and access to commercial tools, paving the way for a biologics license application.
TORL BioTherapeutics, focused on cancer therapies, completed a $158 million Series B funding round in April 2023. The company, led by scientific co-founder Dennis Slamon from UCLA, is developing antibody-drug conjugates and monoclonal antibodies for cancer treatment.
WuXi Biologics made a strategic move in 2020 by acquiring Bayer’s drug manufacturing facility in Germany, marking its first European facility to enhance its commercial production capabilities.
In October 2020, Cadila Pharmaceuticals launched two biosimilar drugs in the Indian market—NuPTH and Cadalimab—expanding its regional footprint.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biologics-market-size
Access exclusive insight now @ https://www.towardshealthcare.com/price/5108
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More